Arvinas (NASDAQ:ARVN) Price Target Raised to $21.00 at Citigroup

Arvinas (NASDAQ:ARVN) had its price objective raised by Citigroup from $18.00 to $21.00 in a report issued on Thursday morning,Benzinga reports. They currently have a buy rating on the stock.

Several other equities analysts have also recently commented on the stock. Wall Street Zen cut shares of Arvinas from a “hold” rating to a “sell” rating in a research note on Monday, March 2nd. Barclays upped their price target on shares of Arvinas from $16.00 to $18.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 17th. Piper Sandler reiterated an “overweight” rating and set a $20.00 price objective (up from $16.00) on shares of Arvinas in a research note on Wednesday, February 25th. Truist Financial set a $10.00 target price on Arvinas in a report on Wednesday. Finally, BTIG Research upped their target price on Arvinas from $14.00 to $16.00 and gave the stock a “buy” rating in a research report on Thursday. Ten research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $13.88.

Arvinas Stock Performance

NASDAQ ARVN opened at $11.17 on Thursday. Arvinas has a one year low of $5.90 and a one year high of $14.51. The company has a 50-day simple moving average of $12.72 and a 200-day simple moving average of $11.13. The firm has a market capitalization of $714.43 million, a PE ratio of -8.73 and a beta of 1.87.

Arvinas (NASDAQ:ARVN) last issued its quarterly earnings data on Tuesday, February 24th. The company reported ($1.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.55). Arvinas had a negative return on equity of 14.25% and a negative net margin of 30.77%.The company had revenue of $9.50 million for the quarter, compared to the consensus estimate of $37.26 million. During the same quarter in the previous year, the company earned ($0.63) earnings per share. Arvinas’s quarterly revenue was down 84.0% compared to the same quarter last year. Equities analysts forecast that Arvinas will post -3.81 earnings per share for the current year.

Insider Buying and Selling

In related news, Director John G. Houston sold 35,297 shares of the stock in a transaction on Friday, February 27th. The stock was sold at an average price of $13.21, for a total transaction of $466,273.37. Following the completion of the sale, the director directly owned 1,122,183 shares in the company, valued at approximately $14,824,037.43. This trade represents a 3.05% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Randy Teel sold 4,786 shares of the firm’s stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $12.16, for a total value of $58,197.76. Following the sale, the chief executive officer directly owned 149,696 shares of the company’s stock, valued at $1,820,303.36. This trade represents a 3.10% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 63,864 shares of company stock valued at $802,443. 4.73% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Arvinas

Large investors have recently added to or reduced their stakes in the stock. TCG Crossover Management LLC bought a new stake in Arvinas during the 3rd quarter valued at approximately $13,780,000. Balyasny Asset Management L.P. grew its holdings in Arvinas by 469.1% in the 3rd quarter. Balyasny Asset Management L.P. now owns 1,207,267 shares of the company’s stock valued at $10,286,000 after buying an additional 995,125 shares during the last quarter. Qube Research & Technologies Ltd increased its position in Arvinas by 154.8% in the 3rd quarter. Qube Research & Technologies Ltd now owns 1,486,864 shares of the company’s stock worth $12,668,000 after buying an additional 903,337 shares during the period. Millennium Management LLC lifted its holdings in shares of Arvinas by 208.4% during the first quarter. Millennium Management LLC now owns 1,310,326 shares of the company’s stock worth $9,198,000 after buying an additional 885,483 shares during the last quarter. Finally, Armistice Capital LLC lifted its holdings in shares of Arvinas by 114.3% during the third quarter. Armistice Capital LLC now owns 1,200,000 shares of the company’s stock worth $10,224,000 after buying an additional 640,000 shares during the last quarter. Institutional investors own 95.19% of the company’s stock.

Trending Headlines about Arvinas

Here are the key news stories impacting Arvinas this week:

• Positive Sentiment: Positive Phase 1 data for ARV-102 showed >50% LRRK2 degradation in CSF after 28 days and reductions in endolysosomal and neuroinflammatory biomarkers—data that de‑risks the Parkinson’s program and increases the drug’s clinical value. Arvinas Announces Positive Phase 1 Data for ARV-102
• Positive Sentiment: Citigroup raised its price target from $18 to $21 and initiated/maintained a Buy rating—an analyst upgrade that implies a large upside and can attract momentum investors. Benzinga
• Positive Sentiment: BTIG bumped its target from $14 to $16 and keeps a Buy rating, providing additional brokerage support for the shares and reinforcing the sentiment shift after the clinical news. Benzinga
• Neutral Sentiment: Short-interest reports for mid‑March show anomalous zero/NaN values and a 0.0 days-to-cover figure—data appears unreliable or miscoded and currently offers no clear sign of increased short pressure. Investors should watch for corrected filings for a clearer picture. TipRanks / Short Interest Note

About Arvinas

Arvinas, Inc (NASDAQ: ARVN) is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body’s natural protein-recycling systems.

The company’s most advanced clinical candidates address hormone-driven cancers.